Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

Study Overview
=================
Brief Summary
-----------------
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis. Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

Detailed Description
-----------------
To determine if patients presenting with type 1 neovascularization believed to be secondary to CSC are genetically distinct from typical CSC patients without neovascularization or patients presenting with choroidal neovascularization (CNV) secondary to advanced AMD. Disease associated markers detecting variants in ARMS 2, Complement Factor H (CFH) Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), VEGFA or other genetic polymorphisms associated with CNV will be evaluated to determine if the CSC neovascular group is genetically distinct from the CSC group without neovascularization or the advanced AMD group.

Official Title
-----------------
Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).

Conditions
-----------------
Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caucasian 30 years and older (CSC) 50 years and older (Advanced AMD) Genders Eligible for Study: Both Completed Consent form Diagnosis of choroidal neovascularization in at least one eye Exclusion Criteria: Patient age less than 30 years (CSC). Patient age less than 50 years (AMD). Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 30. Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate fundus photography. Missing informed consent Previous sample donation under this protocol

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CNV secondary to CSC<br> | |
| CSC without CNV<br> | |
| CNV secondary to advanced AMD<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total genetic burden | The identification of individual genetic markers or a quantitative measure of total genetic burden associated with CNV secondary to CSC vs. CSC vs. CNV secondary to advanced AMD as meaured by the commercially available RetnaGene AMD assay. | Baseline assessment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy